BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19036682)

  • 41. Navigation-assisted localisation and resection of subclinical metastatic malignant melanoma of unknown primary based on 18-fluorodeoxyglcose positron emission tomography computed tomography fusion imaging.
    Ghazali N; Collyer JC; Tighe J
    Int J Oral Maxillofac Surg; 2012 Jan; 41(1):5-8. PubMed ID: 22024137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
    Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
    Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods.
    Krug B; Dietlein M; Groth W; Stützer H; Psaras T; Gossmann A; Scheidhauer K; Schicha H; Lackner K
    Acta Radiol; 2000 Sep; 41(5):446-52. PubMed ID: 11016764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Whole body PET/CT for initial staging of choroidal melanoma.
    Finger PT; Kurli M; Reddy S; Tena LB; Pavlick AC
    Br J Ophthalmol; 2005 Oct; 89(10):1270-4. PubMed ID: 16170114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review.
    Krug B; Crott R; Lonneux M; Baurain JF; Pirson AS; Vander Borght T
    Radiology; 2008 Dec; 249(3):836-44. PubMed ID: 19011184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
    Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
    Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initial staging of malignant melanoma by positron emission tomography and sentinel node biopsy.
    Libberecht K; Husada G; Peeters T; Michiels P; Gys T; Molderez C
    Acta Chir Belg; 2005; 105(6):621-5. PubMed ID: 16438072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients.
    Longo MI; Lázaro P; Bueno C; Carreras JL; Montz R
    Dermatol Surg; 2003 Mar; 29(3):245-8. PubMed ID: 12614417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Melanoma imaging with highly specific PET probes: ready for prime time?
    Minn H; Vihinen P
    J Nucl Med; 2011 Jan; 52(1):5-7. PubMed ID: 21149485
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers.
    Annunziata S; Laudicella R; Caobelli F; Pizzuto DA; Aimn Working Group Y
    Curr Radiopharm; 2020; 13(1):6-13. PubMed ID: 31749438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Second cancers discovered by (18)FDG PET/CT imaging for choroidal melanoma.
    Chin K; Finger PT; Kurli M; Tena LB; Reddy S
    Optometry; 2007 Aug; 78(8):396-401. PubMed ID: 17662928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical value of whole body
    Bower N; Morris A; O'Connor J; Sponagle M; Bahr R; Gilbert R; Mohamed A; Bower J
    J Med Imaging Radiat Sci; 2024 Jun; 55(2):212-220. PubMed ID: 38403520
    [TBL] [Abstract][Full Text] [Related]  

  • 53. F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp.
    Vasanawala MS; Wang Y; Quon A; Gambhir SS
    Clin Nucl Med; 2006 Sep; 31(9):534-7. PubMed ID: 16921276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma.
    Twycross SH; Burger H; Holness J
    S Afr J Surg; 2019 Sep; 57(3):44-49. PubMed ID: 31392864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Melanoma metastasis to the testis demonstrated with FDG PET/CT.
    Weng LJ; Schöder H
    Clin Nucl Med; 2004 Dec; 29(12):811-2. PubMed ID: 15545888
    [No Abstract]   [Full Text] [Related]  

  • 56. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis.
    Rodriguez Rivera AM; Alabbas H; Ramjaun A; Meguerditchian AN
    Surg Oncol; 2014 Mar; 23(1):11-6. PubMed ID: 24556310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
    Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
    Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 18F-FDG PET/CT for staging of penile cancer.
    Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S
    J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Considerations on 18FDG PET/CT and sentinel lymph node biopsy in AJCC stages I and II of melanoma.
    Veronesi G; Ravaioli GM; Lambertini M; Zannetti G; Diodato S; Gardini A; Patrizi A; Fanti S; Dika E
    G Ital Dermatol Venereol; 2020 Dec; 155(6):784-786. PubMed ID: 29998716
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.